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Objective.To examine gastrointestinal (GI) and genitourinary (GU) toxicity proﬁles of patients treated in 1999 with external beam
radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods. TThe records of 525 patients
treated in 1999 were reviewed to evaluate toxicity. Late GI and GU morbidities were graded according to the RTOG late morbidity
criteria. Other factors examined were patient age, BMI, smoking history, and medical co-morbidities. Due to the low event rate
for late GU and GI toxicities, a competing risk regression (CRR) analysis was done with death as the competing event. Results.
Median follow-up time was 8.5 years. On CRR univariate analysis, only the presence of DM was signiﬁcantly associated with GU
toxicity grade >2( P = 0.43, HR 2.35, 95% Cl = 1.03–5.39). On univariate analysis, RT and DM were signiﬁcantly associated with
late GI toxicity. On multivariable analysis, both variables remained signiﬁcant (RT: P = 0.038, HR = 4.71, CI = 1.09–20.3; DM:
P = 0.008, HR = 3.81, 95% Cl = 1.42–10.2). Conclusions. Late eﬀects occur with all treatment modalities. The presence of DM at
the time of treatment was signiﬁcantly associated with worse late GI and GU toxicity. RT was signiﬁcantly associated with worse
late GI toxicity compared to PI and RP.
1.Introduction
For patients with localized prostate cancer, treatment
options include active surveillance, radical prostatectomy
(RP), external beam radiation therapy (RT), or low-dose-
rate prostate interstitial brachytherapy (PI). There is data
showing that in low-risk disease, excellent prostate-speciﬁc
antigen (PSA) relapse-free survival outcomes are obtained
with a low risk of signiﬁcant treatment-related morbidity
[1–4]. Low-risk patients do well with any of the three
treatment modalities but there is no data comparing late
toxicity. Due to lack of randomized data comparing these
modalities, treatment decisions are often made by patient
or physician preference based on the side eﬀect proﬁles
exhibited by each treatment type. While all modalities have
generally similar toxicity proﬁles, there are slight diﬀerences
between each that can impact long-term quality of life [5].
There are reports comparing the late toxicity rates between
diﬀerent types of radiation treatment options with noted
improvement in morbidity with newer treatment techniques
such as intensity-modulated radiation therapy (IMRT) [6].
However, there have been few reports comparing potential
long-term toxicity proﬁles of patients treated with radiation
treatment modalities to those who have undergone surgical2 Prostate Cancer
resection. In the present paper we compare our data on
toxicity for patients treated in 1999 with RP, RT (IMRT), or
PI.
2.MaterialsandMethods
The records of 525 patients treated in 1999 were reviewed
to evaluate toxicity proﬁles. The year 1999 was chosen to
allow for suﬃcient potential follow-up time, and by that
time, all the three treatment programs (RP, RT, and PI) had
been well established for years. Of all patients treated during
the 1999 calendar year we excluded 42 patients for whom
we had no follow-up data, with the excluded patients being
evenlydistributedamongthethreemethodsoftreatment.All
patients were identiﬁed from our prospectively maintained,
IRB-approved prostate cancer registry. Of the 483 patients
with clinical followup, 116 (24%) were treated with PI, 195
(40%) with RP, and 172 (36%) with RT.
Each patient’s medical record was examined with atten-
tion to visits to his urologist, radiation oncologist, internal
medicine,orfamilycarephysicianandanygastroenterologist
since the time of treatment. Late toxicity was deﬁned
as toxicity occurring at least six months after treatment.
Gastrointestinal (GI) and genitourinary (GU) morbidity
proﬁles were speciﬁcally examined and graded according
to the RTOG acute and late morbidity scoring criteria.
The RTOG morbidity scoring criteria is a numeric scoring
system with scores ranging from grade 1 (mild morbidity
not requiring any intervention) to grade 5 (death), with
speciﬁc criteria for GI and GU side eﬀect proﬁles. These
criteria were not eﬀective in describing toxicities experienced
by the group of patients treated with surgical resection,
so the National Cancer Institute’s Common Terminology
Criteria for Adverse Events, (CTCAE) version 4.0, was used
to grade surgical patients’ late morbidity. The CTCAE is
comparable, but not identical to the RTOG late toxicity
scoring system. The CTCAE is generally more descriptive
and comprehensive compared to the RTOG late morbidity
scoring criteria; however there is signiﬁcant overlap in the
described grading systems. For example, the RTOG criteria
donotmentionasurgicalinterventionintheirlateGIscoring
criteria save in the case of grade 3. However, the RTOG
grade 2 late GI scoring criteria include: “moderate diarrhea
and colic; bowel movement >5 times daily; excessive rectal
mucus or intermittent bleeding.” When patients presented
for followup with intermittent bleeding after RT we felt this
was clearly a grade 2 toxicity and not a grade 3, which
the RTOG criteria list as being: “obstruction or bleeding
requiring surgery.” This description of late GI toxicity that
includes intermittent bleeding is similar to the CTCAE
grade 2 GI toxicity which is listed under rectal hemorrhage
as: “moderate symptoms; medical intervention or minor
cauterizationindicated.” ThelateGUtoxicity criteria arealso
slightlydiﬀerentastheRTOGcriterianevermentionsurgical
intervention at all, and late grade 2 toxicity incorporates:
“moderatefrequency;generalizedtelangiectasia;intermittent
macroscopic hematuria.” The CTCAE grade 2 hematuria is
listedasincluding“symptomatic,urinarycatheterorbladder
irrigation indicated; limiting instrumental ADL.” Again, the
scoring systems are comparable, but not identical.
Upon review of the patient’s medical record, at any visit
wherein toxicity was addressed or brought up by the patient,
the speciﬁc GI or GU toxicity was graded according to the
above criteria. Other factors examined were patient age,
body mass index (BMI), smoking history, and medical co-
morbidities including presence of diabetes mellitus (DM),
peripheral vascular disease, and connective tissue disease.
Due to the low event rate and the potential for patients
to have died before developing a late GU or GI toxicity, a
competing risk regression (CRR) analysis was done for each
toxicity endpoint with death as the competing event [7].
The ﬁnal multivariable model was built using the forward,
stepwise procedure. Factors with a P value < 0.05 on a
univariate analysis were included in a multivariable analysis.
Variables having a P value of < 0.05 remained in the ﬁnal
model. Cumulative incidence rates of late GU and GI were
calculated, and comparisons among the three treatment
groups were made using Gray’s test [8]. The competing
risk regression analysis and the cumulative incidence rate
comparisons were performed using R version 2.8.1 (The R
Foundation for Statistical Computing, Vienna, Austria). All
other statistical analyses were done using SAS version 9.2
(SAS Institute, Cary, NC, USA).
2.1. Radical Prostatectomy Group. Patients in the surgical
group underwent RP under the care of surgeons in the
department of urology. The majority underwent open,
retropubic radical prostatectomies. Twelve (6.2%) patients
underwent a laparoscopic prostatectomy or robotic-assisted
prostatectomy. Ninety-eight (50.3%) patients underwent
a bilateral nerve sparing prostatectomy, 20 (10.3%) had
unilateral nerve sparing, and 77 (39.5%) did not undergo a
nerve-sparing prostatectomy. Twenty-three patients (11.8%)
received adjuvant salvage radiation therapy to the prostate.
2.2. External Beam Radiation Therapy Group. All but 11
(6.4%) patients in the EBRT group were treated with IMRT.
The patients were treated under the care of two radiation
oncologists with the general treatment planning guidelines
previously described [9, 10]. In brief, the patients were
treatedwithaﬁve-ﬁeldIMRTplantoatotaldoseof70Gyvia
28 daily fractions of 2.5Gy. This dose and hypofractionated
regimen was the standard at the Cleveland Clinic in 1999.
HypofractionatedIMRTisonemethodofdeliveringexternal
beam radiotherapy. It remains under investigation, with a
phase III trial (RTOG 0415) conducted by the RTOG, with
long-term data maturing. The 11 patients who were not
treated with IMRT were treated with a conformal radiation
treatment plan to a total dose of 78Gy via 39 daily fractions
of 2.0Gy.
The treating physician delineated all target and normal
tissue volumes, with low-risk patients having the target
deﬁned as the prostate only and high-risk patients having
the prostate and seminal vesicles included as the target. The
expansions to obtain a planning target volume (PTV) fromProstate Cancer 3
Table 1: Patient Characteristics.
Characteristic RP (n = 195) RT (n = 172) PI (n = 116) P value
Median age (yrs), (range) 62, (42–75) 68, (48–84) 69, (47–78) <0.0001
Median follow-up time (yrs), (range) 8.6, (1.7–11.2) 8.9, (0.13–11.4) 8.1, (0.16–11.5) 0.08
Median body mass index (m/kg2), (range) 26.92, (19–39) 27.57, (18–42) 27.2, (20–42) 0.07
Ever smoked (%) 65.1 52.9 63.8 0.10
Diabetic (%) 6.7 15.1 10.3 0.02
Peripheral vascular disease (%) 1.5 3.5 7.8 0.02
Connective tissue disease (%) 0.5 0 0 0.48
Mean charlson score (range) 0.3, (0–3) 0.5, (0–7) 0.8, (0–7) <0.0001
Androgen deprivation (%) 16.9 63.4 30.2 <0.0001
Risk category (%) <0.0001
Low 50.8 30.8 75
Intermediate 25.1 29.7 25
High 24.1 39.5 0
the prostate or prostate + seminal vesicles were 4mm pos-
teriorly, 8mm laterally, and 5mm in all other dimensions.
The dose constraints used for treatment planning included
t h et a r g e tv o l u m e( P T V )t o7 0G ywi t har a n g eo f6 5t o7 8G y
withthedoseprescribedtoanisodoselinecoveringthetarget
ranging from 82.0% to 90.0%. The limits that were used
for bladder were no more than 30% to receive greater than
55Gy with maximum level at 74Gy and no more than 30%
of rectum to be greater than 50Gy with maximum dose of
74Gy.
For daily localization, after set-up via triangulation
marks, all patients underwent ultrasound image guidance
using the BAT transabdominal ultrasound system. The
system consists of a B-mode transabdominal ultrasound
probe attached to a precision tracking arm with greater
details described previously [9].
2.3. Prostate Brachytherapy Group. Patients in the brachy-
therapy group underwent PI under the care of one of
two radiation oncologists. The brachytherapy procedure
has been described previously [11]. In brief, patients were
treated with a dose of 144Gy prescribed to the prostate
using I-125 monotherapy. All patients underwent intraop-
erative planning using a transrectal ultrasound probe for
creation of an optimal seed loading pattern that would
allow for delivery of the prescription dose and conform
to established dose constraints for the surrounding normal
tissues. The target volume was deﬁned on the intraoperative
ultrasound axial images and consisted of the prostate only
for low-risk patients and the prostate and 0.5–1cm of
the proximal seminal vesicles for intermediate- and high-
risk patients. A postprocedure CT scan was performed one
month following implantation for the purpose of dosimetric
evaluation. Dosimetric guidelines followed for evaluation
of the brachytherapy consisted of minimum dose to 90%
of the prostate PTV (D90) between 90% and 130% of the
prescribed dose, at least 80% of the prostate PTV to get at
least 100% of the prescribed dose, and the urethral dose
should be limited to 150% of the target dose. The dosimetric
constraint for the rectum was deﬁned as the volume of
rectum receiving 100% of the prescribed dose and it was
limited to be less than 1cc.
Follow-up evaluations were done one month after
treatment for all three modalities. Subsequent follow-up
examinations were done between three to six months and
then yearly for ﬁve years. Following ﬁve years, followup
with either the treating urologist or radiation oncologist
was sporadic; however followup with the primary care
physician was reviewed and coded according to the above-
mentioned toxicity criteria. Most often, if any GI or GU
events occurred and the patient was not currently following
with his radiation oncologist or urologist, the patient was
referredbackforfollowupuponincidenceofthetoxicity.The
median followup time for all groups of patients was 8.5 years
(range 0.1–11.5 years). The median follow-up times for each
group are as follows: RP: 8.6 years, PI: 8.1 years, EBRT: 8.9
years. The patient characteristics of all treatment groups are
shown in Table 1.
3. Results
Overall, all three modalities were associated with relatively
l o wl a t eG Ia n dG Ut o x i c i t yr a t e s .T h ef r e q u e n c yo fl a t e
GU toxicity (grade 2 or higher) was 6.8% for all patients
and was 4.3% for PI patients, 5.1% for RP patients, and
10.5% for RT patients. As demonstrated in Figure 1(a), the
cumulative incidence of long-term GU toxicity (grade 2 or
higher) was highest in patients treated with RT (11.2% at
10 years). Patients treated with RP had the next highest
cumulative incidence of GU toxicity, 5.5% at 10 years,
while the cumulative incidence at 10 years was 4.3% for PI.
There were no GU toxicities noted beyond four years for
PI patients. GU toxicities were observed more than eight
years after treatment for RP patients. The varying types of
late toxicities were slightly diﬀerent following RP compared
to those after PI or RT. The slight variations as well as the
relative frequency are noted in Table 2.
In the competing risk regression univariate analysis,
the presence of DM was associated with higher rates of
GU toxicity (P = 0.043, HR 2.35, 95% CI = 1.03–5.39,4 Prostate Cancer
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Figure 1: (a) Cumulative incidence curves of GU toxicity, ≥grade 2 for patients treated in 1999 with external beam radiation therapy, radical
prostatectomy, or prostate brachytherapy. (b) Cumulative incidence curves of GI toxicity, ≥grade 2 for patients treated in 1999 with either
external beam radiation therapy, radical prostatectomy, or prostate brachytherapy.
Table 2: Distribution of Toxicities Requiring Interventions (Corresponding to grade ≥2).
Modality most common
toxicities GU toxicities no. (%) Modality most common
toxicities GI toxicities no. (%)
RP
Urinary stricture 6 (3.0%)
Incontinence 2 (1.0%)
Urinary leakage 2 (1.0%)
PI PI
Urinary stricture 4 (3.4%) Rectal bleeding 2 (1.7%)
Incontinence 1 (0.8%)
Retention 1 (0.8%)
RT RT
Frequency 5 (2.9%) Rectal bleeding 8 (4.7%)
Hematuria 7 (4.0%) Radiation Proctitis 4 (2.3%)
Retention 6 (3.5%) Increased freq. 2 (1.1%)
Table 3(a)). DM was the only factor that was statistically
signiﬁcant with relation to the onset of late GU toxicity.
Type of treatment was not signiﬁcantly associated with late
GU toxicity. The major causes of GU toxicity were increased
frequency/irritation and varying degrees of incontinence.
The vast majority of toxicities resolved with further followup
or intervention.
T h e r ew e r en ol a t eG It o x i c i t i e s( g r a d e2o rh i g h e r )
observed for patients who underwent RP (Figure 1(b)). The
frequency of late GI toxcitiy (grade 2 or higher) was 3.3% for
all other patients. For patients treated with PI the frequency
was 1.7% and was 8.1% for patients treated with RT. The 10-
year cumulative incidence rate of late GI toxicity was 7.8% in
patients who had RT versus 1.7% for PI patients.
Since there were no events in the RP group, only the
PI and RT patients were included in the CRR analysis for
late GI toxicity grade ≥2. On univariate analysis, RT and
DM were signiﬁcantly associated with late GI toxicity. On
multivariable analysis, both variables remained signiﬁcant
(RT: P = 0.038, HR = 4.71, 95% CI = 1.09–20.3; DM:Prostate Cancer 5
Table 3: (a) Competing risk regression for late GU toxicity (≥2) for
patients treated in 1999. (b) Competing risk regression for late GI
toxicity (≥2) for patients treated with RT or PI in 1999 (n = 282).
(a)
Univariate analysis P value Hazard
ratio 95% CI
Treatment
RP versus PI 0.73 1.21 0.41–3.55
RT versus PI 0.07 2.54 0.94–6.87
RT versus RP 0.06 2.11 0.97–4.59
Age (continuous variable) 0.12 1.04 0.99–1.10
Charlson score 0.52 1.09 0.84–1.42
Peripheral vascular disease (yes
versus no) 0.42 1.81 0.43–7.62
Diabetes (yes versus no) 0.043 2.35 1.03–5.39
Androgen deprivation (yes
versus no) 0.65 0.85 0.41–1.74
Body mass index 0.40 1.03 0.97–1.09
(b)
Univariate analysis P value Hazard
ratio 95% CI
Treatment
EBRT versus BT 0.03 5.10 1.17–22.3
Age (continuous variable) 0.27 1.05 0.96–1.14
Charlson score 0.13 1.21 0.94–1.56
Peripheral vascular disease (yes
versus no) 0.85 1.22 0.17–9
Diabetes (yes versus no) 0.0051 4.2 1.54–11.5
Androgen deprivation (yes
versus no) 0.63 0.78 0.29–2.11
Body mass index 0.88 0.99 0.83–1.17
Multivariable analysis
Diabetes (yes versus no) 0.008 3.81 1.42–10.2
EBRT versus BT 0.038 4.71 1.09–20.3
P = 0.008, HR = 3.81, 95% CI = 1.42–10.2; Table 3(b)). The
major causes of GI toxicity were rectal bleeding and proctitis.
The vast majority of toxicities resolved with further followup
or intervention.
4. Comment
Our results show that patients treated with any of the three
modalities had low rates of late toxicity. The median follow-
up time of 103 months is longer than most retrospective
series or cohort studies examining the toxicities associated
with prostate cancer treatments. We appreciated an increase
in both GU and GI long-term toxicity, in patients with pre-
existing DM. We also observed an increased incidence of
long-term GI toxicity in patients treated with RT relative
to patients treated with RP or PI that was signiﬁcant on
univariate and multivariable analysis. Our data conﬁrmed
that long-term GI toxicity is lower in RP patients compared
with either modality of radiation treatment which correlates
with data from multiple quality-of-life studies [12–14].
Diabetes has been shown to be a known risk factor for
worselong-termtoxicitiesaftertreatmentforprostatecancer.
In the CaPSURE study, a longitudinal disease registry of
men with prostate cancer, men with DM who were treated
with radical prostatectomy had worse urinary control over
a follow-up period of two years [15]. Men with DM have
been shown to have worse late GI and GU side eﬀects
after being treated with 3D conformal radiation therapy
compared to nondiabetic men [16, 17]. In a series from the
British Columbia Cancer Agency, men treated with I-125
brachytherapy and who had DM were more likely to have
late (median followup 57 months) symptomatic ﬂares of GU
toxicity as measured by the International Prostate Symptom
Score (IPSS) [18].
This association of DM with worse long-term morbidity
c o r r e l a t e sw i t har e p o r tf r o mT h o n ge ta l .[ 19]. They
examinedthedatafromtheProstateCancerOutcomesStudy
(PCOS) with speciﬁc attention to the longitudinal eﬀect of
DM on the health-related quality of life (HRQOL) measures
thatwerecollected.Withﬁveyearsoffollowup,theyreported
that men with DM who were diagnosed prior to treatment
had worse HRQOL scores across treatment groups of radical
prostatectomy, radiation therapy, androgen deprivation, or
watchful waiting. Furthermore, diabetic men had the lowest
urinary control and sexual function scores over time. These
diﬀerences in HRQOL remained constant over the ﬁve years
evaluated. There are several reports that show the presence
of DM leads to an increase in all-cause mortality among
patients with prostate cancer, but not an increase in prostate-
cancer-related death, suggesting similar treatment eﬃcacy
[20–24]. Our data further adds that late toxicity is seen more
often in patients with DM compared to those without DM.
Other quality-of-life data that compares all three treat-
ment modalities most often lack prolonged followup. The
PROST-QA trial had 24 months of followup and demon-
stratedtheresolutionofacutemorbiditybutdidnotdescribe
further late toxicity [5]. In contrast with a study done by
Miller et al. that was reported in 2005, our series of patients
shows evolving long-term toxicity with all three types of
treatment modalities [25]. Miller reported on patients who
had received 3D-CRT, PI, or RP, with median time of
followup ranging from 5.4 to 6.5 years since treatment and
noted that patients who had undergone RP were unlikely
to have further toxicity after a period of two years. Patients
in this cohort who underwent RT or PI were more likely
to have long-term emerging toxicity as reported by their
patient-reported quality-of-life outcomes study. Our data,
with median follow-up time ranging from 8.1 to 8.9 years
since treatment, contradicts this ﬁnding as we found in our
series that the cumulative incidence of GU toxicity for RP
patients increased over time, even after ﬁve years. While this
ﬁnding was novel, it is important to note that the cumulative
rate was still low (5.5% at 10 years), and this may be noted in
the cohort reported by Miller with continued followup.
The relative increase in GI toxicity seen in patients who
underwent RT compared to RP and PI could potentially
be attributed to the hypofractionated dose of their IMRT.6 Prostate Cancer
In 1999, when these treatments were performed, the insti-
tutional practice at the Cleveland Clinic was to treat prostate
cancer via hypofractionated IMRT at 2.5Gy/fraction. With
the slightly larger dose per fraction compared to more tradi-
tional dosing (1.8–2.0Gy/fraction), it could be hypothesized
the late eﬀects are results of the 2.5Gy/fraction regimen as
fractionsizeisthedominantfactorindetermininglateeﬀects
from radiotherapy [26]. Earlier reports of the tolerability of
the hypofractionated regimen show it to be comparable to
more standard dose fractionation schemes with regard to
disease control and toxicity rates [27, 28]. These data are
a continuation of followup of a part of the patient cohort
described in the reports by Kupelian et al. and could simply
show that with longer followup late GI toxicity will occur
[28]. However, it is important to note that the cumulative
incidence rate for this toxicity is still low. In a randomized
trial published recently by Yeoh et al. patients treated with
hypofractionated radiation (55Gy/20 fractions) compared
to conventionally fractionated radiation (64Gy/32 fractions)
had equivalent rates of GI and GU toxicity with prospective
toxicity data accrued up to 60 months after treatment,
suggesting further that hypofractionated radiation treatment
has similar toxicity to conventional radiation therapy [29].
While this study lacks the thorough, regimental followup
of prospective clinical trials, it does capture the sort of tox-
icity that will cause a patient to be referred for intervention
(e.g., urinary strictures requiring dilation and rectal bleeding
requiring cauterization). As such, this methodology will not
adequately assess the subjective quality-of-life changes that
equate to a grade I toxicity. It does, however, record the level
of toxicity necessitating intervention and therefore gives a
good estimate of the long-term cost in terms of objective
quality-of-life changes as well as the cost in terms of medical
resources used to deal with the sequelae of treatment.
Further, since it is a retrospective study with physician-
reported data there is a potential to underestimate the level
of toxicity assessed. Patient-reported, prospective data would
have been ideal but was not available. Our study is limited
by the lack of follow-up data on sexual potency, which is an
important factor in overall quality of life following treatment
for prostate cancer.
5. Conclusion
Prostate cancer treatment is associated with low-level long-
term GI and GU toxicity. While the incidence is small, the
diﬀerences among modalities are signiﬁcant. When assessing
the eﬀect of treatment, one must not only account for the
costofinitialtreatment,butalsothecostofhandlingtoxicity.
The presence of diabetes adds to the risk of developing long-
term toxicity.
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